In this issue:
AEs in CAR-T cell therapy
A novel CD19-1XX CAR with calibrated signalling in LBCL
Anti-BCMA CAR-T cell therapy in R/R AL amyloidosis
Real-world ide-cel in R/R multiple myeloma
Immunological sequelae of CAR-T therapy in R/R DLBCL & multiple myeloma
COVID-19 infection in R/R LBCL undergoing CAR-T cell therapy
ICANS risk not altered by baseline cognitive status or prior neurological injury
Brexu-cel in R/R ALL with CNS involvement
Front-line dasatinib + CAR-T cell therapy in newly diagnosed Ph-positive ALL
The clock drawing task to identify ICANS
Please login below to download this issue (PDF)